Influenza vaccine effectiveness research The DRIVE Call for Tenders will be open for the second time in February 2019. The purpose of the call is to support the sharing of existing influenza vaccine effectiveness (IVE) data and to establish new IVE studies which may also include novel and innovative approaches. The call is open to any European organization, institution or network.

The Research Collaborator will be compensated by FISABIO (the DRIVE Coordinator) for data sharing, contribution to the analysis, and participation in project meetings. The allocated budget will be sized according to the associated workload.

The benefits to the Research Collaborator include:

  • Generating robust brand-specific IVE through a European network
  • Implementing potentially innovative approaches for IVE estimation
  • Participation in the scientific discussion and publications process
  • Receiving funding for data sharing and capacity building
  • Participation in the DRIVE Annual Forum and General Assembly.

DRIVE network consists now of 13 research sites from seven European countries. Eight new sites joined the network last year as the result of the first call.

DRIVE is a public-private partnership funded by the Innovative Medicines Initiative. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. DRIVE was established by a consortium of 15 organizations representing European public health institutions, universities, small and medium-sized enterprises, vaccine manufacturers, and patient organizations.

More information on the call will be available at the DRIVE website on January 2019.

Read more

How to participate DRIVE

Contact: In case of any question related to the call, please contact: